In today’s briefing:
- Progyny (PGNY US): Stellar Q4 Results; 2022 Guidance Reiterated on the Back of Business Recovery
Progyny (PGNY US): Stellar Q4 Results; 2022 Guidance Reiterated on the Back of Business Recovery
- Progyny Inc (PGNY US) shares are bouncing off their lows following strong Q4 results and guidance reiteration. Continued stellar growth amid large and underpenetrated TAM call for strong upside potential.
- After impacted by Omicron in December, business activity has rapidly recovered to normal levels this year. Management has guided for 50% y/y revenue growth for 2022.
- For 2022, Progyny added 85 new clients, with 1.2 million covered lives, which will be its long-term growth driver. The company is well-positioned for 70% revenue CAGR during 2021–2024.
Before it’s here, it’s on Smartkarma